Albena D.
- Country
- Bulgaria
- Department
- Endocrinology and Metabolic Diseases Consulting Room
Research Overview
- A Phase 3 Study to Compare the Efficacy and Safety of KAI-9531 Versus Semaglutide in Participants Living with Obesity Without Diabetes
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of KAI-9531 in Adults With Obesity or Overweight and Diabetes
- Randomized Study of Cagrilintide + Semaglutide Combination vs Semaglutide Monotherapy for Weight Loss in Adults with Obesity (± Type 2 Diabetes)
Data & Insights
Has run more than one trial at 86 of 419 partner sites.
Specializations
Weight Management
Specializes in advanced therapeutic approaches for obesity and overweight management, investigating innovative solutions for sustainable weight reduction.
- Medical weight management interventions
- Body weight reduction therapies
- Metabolic health optimization
Focuses on comprehensive treatment strategies combining pharmacological interventions with lifestyle modifications.
Lifestyle Medicine
Integrates reduced-calorie diet protocols and physical activity interventions in weight management programs.
- Dietary intervention strategies
- Exercise program implementation
- Behavioral modification techniques
Develops integrated approaches combining medical treatments with lifestyle interventions.
Therapeutic Innovation
Evaluates novel weight management therapeutics and their effectiveness in treating obesity-related conditions.
- Novel therapeutic agents
- Treatment efficacy assessment
- Weight loss interventions
Investigates cutting-edge treatments for weight management in clinical settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.